MeiraGTx to Acquire bota-vec from Johnson & Johnson

MeiraGTx Holdings has completed the acquisition of botaretigene sparoparvovec (bota-vec), a pharmacy business in New York, for $25 million. MeiraGTx Holdings acquisitions focus on genetic medicines, and bota-vec is an AAV-based gene therapy candidate for X-linked retinitis pigmentosa (XLRP). The botaretigene sparoparvovec (bota-vec) acquisition supports MeiraGTx’s plan to pursue global regulatory filings for U.S., EU, and Japan approvals from New York. The divestiture acquisition is a strategic acquisition by a clinical-stage company, sized at $25M–$50M, under an asset purchase agreement with Johnson & Johnson. MeiraGTx Holdings acquisitions aim to advance a late-stage program with manufacturing and CMC work already completed for regulatory submission.